Medivation, Astellas start Phase III study of prostate cancer drug in bid to widen use
This article was originally published in Scrip
Executive Summary
Medivation and Astellas Pharma said they have started a Phase III study of Xtandi in patients with non-metastatic castration-resistant prostate cancer, a condition for which there is no approved medicine in the US.